Sutro Biopharma Inc
NASDAQ:STRO

Watchlist Manager
Sutro Biopharma Inc Logo
Sutro Biopharma Inc
NASDAQ:STRO
Watchlist
Price: 1.93 USD 3.21% Market Closed
Market Cap: 159.1m USD
Have any thoughts about
Sutro Biopharma Inc?
Write Note

EV/EBIT
Enterprise Value to EBIT

1.8
Current
0.1
Median
4
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
1.8
=
Enterprise Value
-229.2m USD
/
EBIT
-130m USD
All Countries
Close
Market Cap EV/EBIT
US
Sutro Biopharma Inc
NASDAQ:STRO
159m USD 1.8
FR
Pharnext SCA
OTC:PNEXF
6T USD -217 673.3
US
Abbvie Inc
NYSE:ABBV
318.1B USD 23.9
US
Amgen Inc
NASDAQ:AMGN
142.2B USD 30.5
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD 22.7
US
Epizyme Inc
F:EPE
94.1B EUR -499.5
AU
CSL Ltd
ASX:CSL
135.7B AUD 24.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 17.1
US
Seagen Inc
F:SGT
39.3B EUR -52.9
NL
argenx SE
XBRU:ARGX
36.2B EUR -79.9
EBIT Growth EV/EBIT to Growth
US
Sutro Biopharma Inc
NASDAQ:STRO
Average EV/EBIT: 18.7
1.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 673.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.9
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.5
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -499.5 N/A N/A
AU
CSL Ltd
ASX:CSL
24.7
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.9 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
0.9
2-Years Forward
EV/EBIT
0.8
3-Years Forward
EV/EBIT
0.7

See Also

Discover More